PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
Portfolio Pulse from Lara Goldstein
PharmaTher Holdings has partnered with Vitruvias Therapeutics for the commercialization of its proprietary racemic ketamine products, KETARX, in the U.S. market. PharmaTher will be responsible for regulatory, manufacturing, and supply, while Vitruvias will handle marketing, sales, and distribution. PharmaTher plans to file its Abbreviated New Drug Application (ANDA) for KETARX with the FDA in early July and expects approval in Q1 2024.
June 21, 2023 | 2:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PharmaTher's partnership with Vitruvias Therapeutics for KETARX commercialization in the U.S. market could boost its revenue and market presence.
The partnership with Vitruvias Therapeutics will help PharmaTher commercialize its KETARX product in the U.S. market, potentially increasing its revenue and market presence. The company's focus on obtaining regulatory approvals and commercializing KETARX worldwide for unmet medical needs could further enhance its growth prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100